Expands its exclusive rights to allergic rhinitis treatment Dymista
Meda, a specialist Swedish pharmaceutical firm, is broadening its collaboration with Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista and future product development.
Through the extended partnership, Meda will have full coverage in all growth markets in Latin America, South America, Middle East, Africa and Asia, including more than 120 new markets.
Meda and Cipla will cooperate on product development of allergic rhinitis treatment Dymista. Cipla will be responsible for formulation, with Meda handling clinical development, registration, marketing and sales. The companies will also collaborate on future production of Dymista and any new products developed.
‘Through this expanded partnership, we secure opportunities for global commercialisation of Dymista and optimise future product development,’ said Anders Lönner, Meda’s CEO. ‘Not least, we see great potential in several priority growth markets such as China.’
Meda’s product portfolio is divided into three main areas of specialist products, over-the-counter medicines and branded generics.